FDA Going Through Enforcement Toolkit To Address Bentonite Me Baby
This article was originally published in The Rose Sheet
Executive Summary
FDA lab analysis found lead in Alikay Naturals' Bentonite Me Baby clay at a level of 37.5 ppm, according to a March 16 warning letter citing the purported cosmetic as an unapproved and misbranded drug. The agency cautioned consumers about the product in January and seems to be urging the company to recall it, which may draw attention to the authority FDA currently lacks under federal food, drug and cosmetic law.
You may also be interested in...
FDA Issues Second Warning This Year For Bentonite Clay Lead, Claims
Following a January consumer alert and March warning letter to Alikay Naturals for high lead levels, unapproved drug claims and mislabeling issues related to Bentonite Me Baby, FDA comes down on Best Bentonite for similar issues in a warning letter published Nov. 22.
Feinstein, EWG Gunning For Spring Senate Hearing On Cosmetics Bill
During a March 1 press call, the Environmental Working Group highlighted findings from an 800-person survey indicating that 68% of men and women likely to vote this fall support increased government oversight of cosmetic chemicals. Senator Dianne Feinstein touted her proposed Personal Care Products Safety Act as the answer to consumer concerns, hopeful that a Senate committee hearing will be held in the spring.
FDA Warns Public About Products Posing Heavy-Metal Exposure Risks
FDA lab analysis of Alikay Naturals' Bentonite Me Baby identified elevated lead levels posing potential risks to consumers, the agency says in a Jan. 28 safety alert, while the company suggests FDA has mischaracterized its product and intended use. A same-day consumer warning cites hazardous mercury content in a skin cream largely available in Spanish-speaking communities.